(CTOR) Citius Oncology - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •
CTOR: Cancer, Therapies, Oncology, Lymphoma, Treatments
Citius Oncology, Inc. (NASDAQ:CTOR) is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies targeting unmet medical needs. The company’s lead candidate, LYMPHIR, is under development for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), an orphan indication. This rare skin cancer affects immune cells and has limited treatment options. Citius Oncology operates as a subsidiary of Citius Pharmaceuticals, Inc., and is headquartered in New York, New York.
From a technical standpoint, CTOR has shown recent price weakness, with its SMA 20 and SMA 50 below the SMA 200, indicating bearish momentum. The stock’s ATR of 0.14 suggests moderate volatility. On the fundamental side, the company’s market cap of $116.23M reflects its developmental stage. The P/B ratio of 4.55 indicates a premium valuation relative to book value, while the negative RoE of -16.13% highlights ongoing losses typical of early-stage biotech firms.
3-Month Forecast: Based onAdditional Sources for CTOR Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CTOR Stock Overview
| Market Cap in USD | 116m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| GiC Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2022-12-08 |
CTOR Stock Ratings
| Growth 5y | -36.4% |
| Fundamental | -35.1% |
| Dividend | 0.0% |
| Rel. Strength Industry | -98 |
| Analysts | 4/5 |
| Fair Price Momentum | 0.68 USD |
| Fair Price DCF | - |
CTOR Dividends
No Dividends PaidCTOR Growth Ratios
| Growth Correlation 3m | 5.9% |
| Growth Correlation 12m | -53.4% |
| Growth Correlation 5y | -53.4% |
| CAGR 5y | -98.05% |
| CAGR/Max DD 5y | -1.00 |
| Sharpe Ratio 12m | -1.22 |
| Alpha | -113.98 |
| Beta | 2.20 |
| Volatility | 115.07% |
| Current Volume | 40.7k |
| Average Volume 20d | 42.9k |
As of March 14, 2025, the stock is trading at USD 0.79 with a total of 40,657 shares traded.
Over the past week, the price has changed by -23.40%, over one month by -35.85%, over three months by -26.26% and over the past year by -98.05%.
Probably not. Based on ValueRay Fundamental Analyses, Citius Oncology (NASDAQ:CTOR) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -35.06 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CTOR as of March 2025 is 0.68. This means that CTOR is currently overvalued and has a potential downside of -13.92%.
Citius Oncology has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy CTOR.
- Strong Buy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CTOR Citius Oncology will be worth about 0.8 in March 2026. The stock is currently trading at 0.79. This means that the stock has a potential upside of +2.53%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 0.8 | 2.5% |